Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTO1 | P78417 | 2/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22905551 | 1.00 | GSTO1 (0.42) | GSTO1NLRP3POLB | |
| SCHEMBL22905438 | 0.90 | NLRP3 (0.39) | GSTO1NLRP3POLB | |
| SCHEMBL22905443 | 0.90 | NLRP3 (0.39) | GSTO1NLRP3POLB | |
| SCHEMBL22905448 | 0.87 | NLRP3 (0.41) | GSTO1NLRP3POLB | |
| SCHEMBL22905670 | 0.87 | NLRP3 (0.41) | GSTO1NLRP3POLB | |
| SCHEMBL24774207 | 0.87 | NLRP3 (0.52) | GSTO1NLRP3 | |
| SCHEMBL22905436 | 0.87 | NLRP3 (0.52) | GSTO1NLRP3 | |
| SCHEMBL30155073 | 0.87 | NLRP3 (0.52) | GSTO1NLRP3 | |
| SCHEMBL22905540 | 0.85 | POLB (0.39) | GSTO1NLRP3POLB | |
| SCHEMBL22905535 | 0.85 | POLB (0.39) | GSTO1NLRP3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466800-B2 | N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4, 5, 6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS) | ZOMAGEN BIOSCIENCES LTD (US) | 2025-11-11 | — | — | US | disclosed |
| US-20220396559-A1 | N-((1,2,3.5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4, 5, 6, 7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) | ZOMAGEN BIOSCIENCES LTD | 2022-12-15 | — | — | US | disclosed |
| US-20220396559-A1 | N-((1,2,3.5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4, 5, 6, 7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) | ZOMAGEN BIOSCIENCES LTD | 2022-12-15 | — | — | US | disclosed |
| WO-2021009566-A1 | N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4,5,6,7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) | ZOMAGEN BIOSCIENCES LTD (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466800-B2 | N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4, 5, 6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS) | FFAR3, NLRP3, NOD1 | GSTO1 3077/4885NLRP3 2/4885POLB 4828/4885 |
| US-20220396559-A1 | N-((1,2,3.5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4, 5, 6, 7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) | GLS2, FFAR3, FABP1 | GSTO1 2157/4885NLRP3 197/4885POLB 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.